Evaluation of pharmacokinetics and safety profiles between S-1 granule and S-1 capsule in patients with solid tumors

被引：0
|
作者：
Takahashi, T. [1 ]
Hironaka, S. [2 ]
Yasui, H. [2 ]
Endo, M. [3 ]
Nakamura, Y. [1 ]
Yamamoto, N. [1 ]
Boku, N. [2 ]
机构：
[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[3] Shizuoka Canc Ctr, Div Endoscope, Shizuoka, Japan
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70463-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [21] The unanswered question: What is the determinant of S-1 pharmacokinetics?
    Ichikawa, W.
    Fujita, K.
    Sasaki, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) : 203 - 203
  • [22] Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
    van Groeningen, CJ
    Peters, GJ
    Schornagel, JH
    Gall, H
    Noordhuis, P
    de Vries, MJ
    Turner, SL
    Swart, MS
    Pinedo, HM
    Hanauske, AR
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) : 2772 - 2779
  • [23] S-1 SPHEROMAK
    YAMADA, M
    NUCLEAR FUSION, 1985, 25 (09) : 1327 - 1330
  • [24] Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients
    Chen, Yong
    Jiang, Yun
    Qu, Jingjing
    Wang, Qiming
    Bai, Yuxian
    Shi, Jianhua
    Shi, Yehui
    Chen, Xue
    Yang, Nong
    Heng, Jianfu
    Li, Kunyan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 151
  • [25] Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?
    Jaffer A Ajani
    Nature Clinical Practice Oncology, 2008, 5 : 508 - 509
  • [26] Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?
    Ajani, Jaffer A.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (09): : 508 - 511
  • [27] Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma
    Furuse, Junji
    Okusaka, Takuji
    Kaneko, Shuichi
    Kudo, Masatoshi
    Nakachi, Kohei
    Ueno, Hideki
    Yamashita, Tatsuya
    Ueshima, Kazuomi
    CANCER SCIENCE, 2010, 101 (12) : 2606 - 2611
  • [28] Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment
    Chen, Siying
    Sun, Jifeng
    Zhao, Lujun
    Sun, Yunguang
    Jia, Dan
    Song, Yongchun
    Luo, Jing
    Lei, Hailong
    Liu, Ningbo
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
  • [29] Pharmacokinetics of intraperitoneal docetaxel and S-1 in patients with gastric cancer with peritoneal carcinomatosis
    Hayashi, K.
    Kamikozuru, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in western and Japanese patients
    Comets, E
    Ikeda, K
    Hoff, P
    Fumoleau, P
    Wanders, J
    Tanigawara, Y
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2003, 30 (04) : 257 - 283
12345